SEC Comment Letter 0000000000-26-004583 to Onconetix, Inc. (ONCO)
Onconetix, Inc.
Date: May 5, 2026 · CIK: 0001782107 · Accession: 0000000000-26-004583
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295376
Letter
May 5, 2026 David A. White Chief Executive Officer Onconetix, Inc. 201 E. Fifth Street, Suite 1900 Cincinnati, Ohio 45202 Re: Onconetix, Inc. Registration Statement on Form S-1 Filed April 28, 2026 File No. 333-295376 Dear David A. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica Yuan, Esq.
Show Raw Text
May 5, 2026 David A. White Chief Executive Officer Onconetix, Inc. 201 E. Fifth Street, Suite 1900 Cincinnati, Ohio 45202 Re: Onconetix, Inc. Registration Statement on Form S-1 Filed April 28, 2026 File No. 333-295376 Dear David A. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica Yuan, Esq.